The immuno-oncological challenge of COVID-19

[1]  O. Cortés,et al.  Systematic review and meta-analysis of clinical trials , 2021, Medicine.

[2]  Yang Wu,et al.  SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 , 2020, Nature Communications.

[3]  N. Chaput,et al.  Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort , 2020, Nature Cancer.

[4]  Krystal L. Matthews,et al.  Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.

[5]  I. Bennani-Baiti,et al.  Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy , 2020, Annals of Oncology.

[6]  G. Corrao,et al.  Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[7]  S. Halstead,et al.  COVID 19 Vaccines: Should we fear ADE? , 2020, The Journal of infectious diseases.

[8]  G. Lip,et al.  Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated , 2020, Journal of Human Hypertension.

[9]  J. C. Belmonte,et al.  A human circulating immune cell landscape in aging and COVID-19 , 2020, Protein & Cell.

[10]  K. Qu,et al.  Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm , 2020, Nature Communications.

[11]  I. Amit,et al.  Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 , 2020, Cell.

[12]  A. Iwasaki,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, The Journal of experimental medicine.

[13]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[14]  L. Zitvogel,et al.  On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2 , 2020, Cell Death & Disease.

[15]  M. Rugge,et al.  SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer , 2020, Nature Cancer.

[16]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[17]  Á. Avezum,et al.  Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 , 2020, The New England journal of medicine.

[18]  D. Giugliano,et al.  Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies , 2020, Cardiovascular Diabetology.

[19]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[20]  M. Chua,et al.  Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors , 2020, Cancer communications.

[21]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[22]  Peter Y. Kim,et al.  Opportunities for improved cardiovascular disease prevention in oncology patients. , 2020, Current opinion in cardiology.

[23]  Chengliang Zhu,et al.  Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19 , 2020, Frontiers in Molecular Biosciences.

[24]  E. Robilotti,et al.  Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.

[25]  Quanlong Jiang,et al.  Individual variation of the SARS‐CoV‐2 receptor ACE2 gene expression and regulation , 2020, Aging cell.

[26]  A. Drilon,et al.  COVID-19 in patients with lung cancer , 2020, Annals of Oncology.

[27]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[28]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[29]  Trevor Bedford,et al.  Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California , 2020, Science.

[30]  J. Blay,et al.  High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR , 2020, European Journal of Cancer.

[31]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[32]  Yun‐Sil Lee,et al.  Radiation-Induced Lung Fibrosis: Preclinical Animal Models and Therapeutic Strategies , 2020, Cancers.

[33]  O. Tsang,et al.  Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses , 2020, Immunity.

[34]  G. Chatellier,et al.  Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.

[35]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[36]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[37]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[38]  B. Ebert,et al.  The impact of the COVID-19 pandemic on cancer care , 2020, Nature Cancer.

[39]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[40]  C. Koval,et al.  Antivirals for COVID-19. , 2020, Cleveland Clinic journal of medicine.

[41]  P. Mordant,et al.  Low doses of radiation therapy increase the immunosuppressive profile of lung macrophages via IL-10 production and IFNγ/IL-6 suppression: a therapeutic strategy to counteract lung inflammation? , 2020 .

[42]  M. Kamboj,et al.  COVID-19 in Children With Cancer in New York City. , 2020, JAMA oncology.

[43]  I. Youngster,et al.  SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. , 2020, JAMA.

[44]  N. Tentolouris,et al.  In vitro data of current therapies for SARS-CoV-2. , 2020, Current medicinal chemistry.

[45]  J. Wolchok,et al.  Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers , 2020, Cancer discovery.

[46]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[47]  R. Weichselbaum,et al.  Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable☆ , 2020, Radiotherapy and Oncology.

[48]  J. Thériault,et al.  Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks , 2020, The journal of physical chemistry letters.

[49]  M. Piris,et al.  Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies , 2020, British journal of haematology.

[50]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[51]  M. Aghili,et al.  Radiotherapy and COVID-19: Practical recommendations from iran☆☆☆ , 2020, Radiotherapy and Oncology.

[52]  L. Baglietto,et al.  The CoV-2 outbreak: how hematologists could help to fight Covid-19 , 2020, Pharmacological Research.

[53]  M. Rugge,et al.  Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) , 2020, Annals of Oncology.

[54]  Zhìhóng Hú,et al.  The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro , 2020, Cell Discovery.

[55]  A. Addeo,et al.  COVID-19 and lung cancer: risks, mechanisms and treatment interactions , 2020, Journal for immunotherapy of cancer.

[56]  J. Cosset,et al.  [Low dose lung radiotherapy for COVID-19-related cytokine storm syndrome: Why not?] , 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[57]  P. Cobbold,et al.  Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease , 2020, Brain sciences.

[58]  J. Mazeron,et al.  Irradiation pulmonaire à faible dose pour l’orage de cytokines du COVID-19 : pourquoi pas ? , 2020, Cancer/Radiothérapie.

[59]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[60]  J. Wolchok,et al.  The many faces of the anti-COVID immune response , 2020, The Journal of experimental medicine.

[61]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[62]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[63]  P. Marik,et al.  Does vitamin D status impact mortality from SARS-CoV-2 infection?☆ , 2020, Medicine in Drug Discovery.

[64]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[65]  Hans Clevers,et al.  SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.

[66]  D. Raoult,et al.  In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect , 2020, Microbial Pathogenesis.

[67]  Fabian J Theis,et al.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.

[68]  V. Wiwanitkit,et al.  COVID-19, radiotherapy and cancer☆ , 2020, Radiotherapy and Oncology.

[69]  M. Müller,et al.  Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[70]  Zhenzhen Zhao,et al.  Strategies for patient with cancer during COVID‐19 pandemic , 2020, Asia-Pacific journal of clinical oncology.

[71]  S. Treon,et al.  The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients , 2020, Blood.

[72]  M. Banach,et al.  Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2 , 2020, Archives of medical science : AMS.

[73]  B. Blomberg,et al.  The Impact of Obesity and Metabolic Syndrome on Vaccination Success. , 2020, Interdisciplinary topics in gerontology and geriatrics.

[74]  C. Mannelli.  Whose life to save? Scarce resources allocation in the COVID-19 outbreak , 2020, Journal of Medical Ethics.

[75]  Dong Yang,et al.  Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  Y. Yazdanpanah,et al.  Type 1 interferons as a potential treatment against COVID-19 , 2020, Antiviral Research.

[77]  Xuhui Huang,et al.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.

[78]  Hui Guo,et al.  First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab , 2020, Blood Advances.

[79]  N. Chaput,et al.  Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report , 2020, Annals of Oncology.

[80]  Ji-Man Kang,et al.  Epidemiology and clinical features of coronavirus disease 2019 in children , 2020, Clinical and experimental pediatrics.

[81]  R. Muniyappa,et al.  COVID-19 pandemic, coronaviruses, and diabetes mellitus , 2020, American journal of physiology. Endocrinology and metabolism.

[82]  D. Hu,et al.  Radiotherapy workflow and protection procedures during the Coronavirus Disease 2019 (COVID-19) outbreak: Experience of the Hubei Cancer Hospital in Wuhan, China☆ , 2020, Radiotherapy and Oncology.

[83]  Krystal L. Matthews,et al.  SARS-CoV-2 in vitro and SARS-CoV in vivo , 2020 .

[84]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[85]  G. Iacobellis.  COVID-19 and diabetes: Can DPP4 inhibition play a role? , 2020, Diabetes Research and Clinical Practice.

[86]  M. Chua,et al.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China , 2020, JAMA oncology.

[87]  L. Boon,et al.  Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination , 2020, eLife.

[88]  Lanjuan Li,et al.  SARS-CoV-2: virus dynamics and host response , 2020, The Lancet Infectious Diseases.

[89]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[90]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[91]  Han-Ming Shen,et al.  Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 , 2020, International journal of biological sciences.

[92]  Fabian J Theis,et al.  SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways , 2020, Nature Medicine.

[93]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[94]  P. Chiusolo,et al.  Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab , 2020, Bone Marrow Transplantation.

[95]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[96]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[97]  Li Zhang,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[98]  Chengyu Jiang,et al.  Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury , 2020, PLoS pathogens.

[99]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[100]  M. Chua,et al.  SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan , 2020, medRxiv.

[101]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[102]  B. Canard,et al.  The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade , 2020, Antiviral Research.

[103]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[104]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[105]  A. Phelan,et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.

[106]  G. Shulman,et al.  Mechanistic Links between Obesity, Insulin, and Cancer. , 2020, Trends in cancer.

[107]  Hongzhou Lu,et al.  Drug treatment options for the 2019-new coronavirus (2019-nCoV). , 2020, Bioscience trends.

[108]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[109]  Yu Wu,et al.  Nivolumab treatment for relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistocytosis in adults. , 2020, Blood.

[110]  L. Zitvogel,et al.  COVID-19: a challenge for oncology services , 2020, Oncoimmunology.

[111]  Naveen Vankadari,et al.  Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 , 2020, Emerging microbes & infections.

[112]  Highlights. , 2020, JAMA internal medicine.

[113]  Cindy Leung,et al.  Association of a Workplace Sales Ban on Sugar-Sweetened Beverages With Employee Consumption of Sugar-Sweetened Beverages and Health. , 2020, JAMA internal medicine.

[114]  M. Leist,et al.  Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain , 2019, Oncogene.

[115]  E. Haddad,et al.  GX15–070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma , 2019, BMC Cancer.

[116]  S. Meuth,et al.  Skeletal muscle as potential central link between sarcopenia and immune senescence , 2019, EBioMedicine.

[117]  M. Frieman,et al.  Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. , 2019, JCI insight.

[118]  P. Thulasiraman,et al.  Neuraminidase 1 regulates proliferation, apoptosis and the expression of Cadherins in mammary carcinoma cells , 2019, Molecular and Cellular Biochemistry.

[119]  D. Schadendorf,et al.  Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade , 2019, Cell Research.

[120]  Xi Chen,et al.  The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications , 2019, Front. Oncol..

[121]  David K. Meyerholz,et al.  IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. , 2019, The Journal of clinical investigation.

[122]  Lulu Qin,et al.  The association between vitamin D deficiency and community-acquired pneumonia , 2019, Medicine.

[123]  A. Hidalgo-Miranda,et al.  Growth inhibition and transcriptional effects of ribavirin in lymphoma. , 2019, Oncology reports.

[124]  J. Debnath,et al.  Targeting Autophagy in Cancer: Recent Advances and Future Directions. , 2019, Cancer discovery.

[125]  K. Schmader,et al.  Age-related changes in B cell metabolism , 2019, Aging.

[126]  M. Vooijs,et al.  The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to γ-secretase inhibition , 2019, Oncogene.

[127]  L. Joosten,et al.  Therapeutic targeting of trained immunity , 2019, Nature Reviews Drug Discovery.

[128]  F. Gao,et al.  Hydroxychloroquine enhances the antitumor effects of BC001 in gastric cancer , 2019, International journal of oncology.

[129]  K. Hahm,et al.  Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein–Barr Virus-Infected Gastric Cancer Cells , 2019, Molecules and cells.

[130]  M. Mauro,et al.  A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer , 2019, Front. Oncol..

[131]  M. Volpe,et al.  Arterial hypertension in cancer: The elephant in the room. , 2019, International journal of cardiology.

[132]  J. Blay,et al.  Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? , 2019, Journal of Immunotherapy for Cancer.

[133]  E. Mazzon,et al.  Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo , 2019, Investigational New Drugs.

[134]  J. Manson,et al.  Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease , 2019, The New England journal of medicine.

[135]  Lixin Wei,et al.  Inhibition of Autophagy with Chloroquine Enhanced Sinoporphyrin Sodium Mediated Photodynamic Therapy-induced Apoptosis in Human Colorectal Cancer Cells , 2019, International journal of biological sciences.

[136]  Jing Zhu,et al.  Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. , 2019, Lung cancer.

[137]  W. Ning,et al.  Advances in Molecular Mechanisms and Treatment of Radiation-Induced Pulmonary Fibrosis , 2018, Translational oncology.

[138]  R. Greil,et al.  Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma , 2019, Annals of Hematology.

[139]  R. Marioni,et al.  Trajectories of inflammatory biomarkers over the eighth decade and their associations with immune cell profiles and epigenetic ageing , 2018, Clinical Epigenetics.

[140]  K. Murphy,et al.  Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation , 2018, Cancer Immunology Research.

[141]  L. Zitvogel,et al.  PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade , 2018, British Journal of Cancer.

[142]  N. Heerema,et al.  Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia , 2018, Oncogene.

[143]  Xiao-ming Xu,et al.  Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. , 2018, Biochemical and biophysical research communications.

[144]  Jichao Ma,et al.  Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma , 2018, Cell Death & Disease.

[145]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[146]  Amanda J. Lee,et al.  The Dual Nature of Type I and Type II Interferons , 2018, Front. Immunol..

[147]  D. Trégouët,et al.  Human thymopoiesis is influenced by a common genetic variant within the TCRA-TCRD locus , 2018, Science Translational Medicine.

[148]  David A. Jolliffe,et al.  Vitamin D receptor genotype influences risk of upper respiratory infection. , 2018, The British journal of nutrition.

[149]  G. Smaldone.  Repurposing of gamma interferon via inhalation delivery , 2018, Advanced drug delivery reviews.

[150]  J. Fellay,et al.  Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines , 2018, Genome Medicine.

[151]  Song Gao,et al.  Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma , 2018, World journal of gastroenterology.

[152]  Xiaofei Wang,et al.  Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo , 2018, Cancer communications.

[153]  Ling Wang,et al.  Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer. , 2018, Biochemical and biophysical research communications.

[154]  N. Mohan,et al.  Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. , 2018, Antibody therapeutics.

[155]  A. Sato,et al.  Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells , 2018, AntiCancer Research.

[156]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[157]  Li Feng,et al.  The PERK Arm of the Unfolded Protein Response Negatively Regulates Transmissible Gastroenteritis Virus Replication by Suppressing Protein Translation and Promoting Type I Interferon Production , 2018, Journal of Virology.

[158]  C. Verschraegen,et al.  Novel organometallic chloroquine derivative inhibits tumor growth , 2018, Journal of cellular biochemistry.

[159]  Benjamin Geiger,et al.  Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection , 2018, Science.

[160]  I. Martínez,et al.  Vitamin D in Human Immunodeficiency Virus Infection: Influence on Immunity and Disease , 2018, Front. Immunol..

[161]  L. Zitvogel,et al.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy , 2018, Oncoimmunology.

[162]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[163]  N. Katabi,et al.  Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus‐associated oropharyngeal squamous cell cancer , 2018, Head & neck.

[164]  C. Eberhart,et al.  Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors , 2018, Oncotarget.

[165]  Yao-ren Hu,et al.  Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin‐induced eIF4E activation , 2018, Journal of biochemical and molecular toxicology.

[166]  G. Pawelec,et al.  Age and immunity: What is “immunosenescence”? , 2017, Experimental Gerontology.

[167]  J. Cao,et al.  Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma , 2018, Clinical and Translational Oncology.

[168]  J. Fellay,et al.  Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges , 2017, Proceedings of the National Academy of Sciences.

[169]  Yi Huang,et al.  Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[170]  Q. Luo,et al.  Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system , 2017, Molecular medicine reports.

[171]  A. Pandiella,et al.  Neutrophils in cancer: prognostic role and therapeutic strategies , 2017, Molecular Cancer.

[172]  Yali Zhu,et al.  Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E‐&bgr;‐Catenin Axis☆ , 2017, The American journal of the medical sciences.

[173]  M. Szewczuk,et al.  Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival , 2017, Drug design, development and therapy.

[174]  A. Thorburn,et al.  Targeting autophagy in cancer , 2017, Nature Reviews Cancer.

[175]  A. Mangraviti,et al.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic , 2017, Oncogene.

[176]  V. Meier-Stephenson,et al.  The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia , 2017, OncoTargets and therapy.

[177]  Jie Huang,et al.  Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer , 2017, Oncology letters.

[178]  I. Vitale,et al.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications , 2017, Oncoimmunology.

[179]  R. Moots.  THE CHALLENGES OF RARE RHEUMATIC DISEASESI79. CHALLENGES OF DIAGNOSING AND MANAGING PATIENTS WITH RARE DISEASES , 2017 .

[180]  B. Kennedy,et al.  Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse. , 2017, Cancer discovery.

[181]  R. Moots,et al.  Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials , 2016, Rheumatology.

[182]  A. Salazar,et al.  Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model , 2016, Antiviral Research.

[183]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[184]  Y. Moustafa,et al.  Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[185]  A. Anel,et al.  Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo. , 2016, Cancer letters.

[186]  J. Yun,et al.  Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. , 2016, Cancer letters.

[187]  E. Sartori,et al.  The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines , 2016, Oncology letters.

[188]  R. Kariya,et al.  Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress , 2016, Apoptosis.

[189]  M. Frieman,et al.  Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion , 2016, Journal of Virology.

[190]  L. Zitvogel,et al.  Immunological off-target effects of imatinib , 2016, Nature Reviews Clinical Oncology.

[191]  R. Baric,et al.  Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.

[192]  K. Wieczorowska-Tobis,et al.  Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study , 2016, Immunity & Ageing.

[193]  H. Ertl,et al.  Aging: T cell metabolism within tumors , 2016, Aging.

[194]  H. Kohrt,et al.  Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. , 2016, The Journal of investigative dermatology.

[195]  Dong Eun Kim,et al.  Chloroquine enhances TRAIL-mediated apoptosis through up-regulation of DR5 by stabilization of mRNA and protein in cancer cells , 2016, Scientific Reports.

[196]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[197]  Reiner Schulz,et al.  Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events , 2016, Nature Immunology.

[198]  I. Ray-Coquard,et al.  Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay , 2015, Oncoimmunology.

[199]  S. Ōmura,et al.  Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines , 2015, International journal of oncology.

[200]  Chuan Qin,et al.  Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways , 2015, The Journal of infectious diseases.

[201]  B. Brown,et al.  Cell Therapy Strategies to Combat Immunosenescence , 2015, Organogenesis.

[202]  E. Cavalli,et al.  The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. , 2015, Leukemia research.

[203]  Wen-ying Lee,et al.  Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1 , 2015, Oncotarget.

[204]  M. Humbert,et al.  Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. , 2015, Circulation.

[205]  Matthew L Albert,et al.  Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy , 2015, Nature Immunology.

[206]  H. Kuramoto,et al.  The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. , 2015, Gynecologic oncology.

[207]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[208]  M. Katze,et al.  Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection , 2015, mBio.

[209]  Mårten Fryknäs,et al.  Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer , 2015, Molecular Cancer Therapeutics.

[210]  M. Vasconcelos,et al.  Anti-Influenza Neuraminidase Inhibitor Oseltamivir Phosphate Induces Canine Mammary Cancer Cell Aggressiveness , 2015, PloS one.

[211]  T. Bridson,et al.  Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections , 2015, Immunology.

[212]  Xiao-fang Xie,et al.  The Alteration and Clinical Significance of Th1/Th2/Th17/Treg Cells in Patients with Multiple Myeloma , 2015, Inflammation.

[213]  S. Singhal,et al.  Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin , 2014, Clinical Cancer Research.

[214]  T. Thamboo,et al.  Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. , 2014, Immunity.

[215]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[216]  W. Oberaigner,et al.  Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria , 2014, BMC Public Health.

[217]  Koichi Araki,et al.  Autophagy is essential for effector CD8 T cell survival and memory formation , 2014, Nature Immunology.

[218]  Mary Beth Tribble,et al.  PTH1-34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival. , 2014, Bone.

[219]  Leslie A. Hamilton,et al.  Interstitial Pneumonitis from Treatment with Gemcitabine , 2014, Hospital pharmacy.

[220]  P. Nelson,et al.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. , 2014, Cancer discovery.

[221]  Ana Maria Cuervo,et al.  Autophagy and the immune function in aging. , 2014, Current opinion in immunology.

[222]  João Costa,et al.  [Analysis of the Cochrane Review: Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. 2014, 6:CD007469]. , 2014, Acta medica portuguesa.

[223]  E. Giovannucci,et al.  Vitamin D supplements and cancer incidence and mortality: a meta-analysis , 2014, British Journal of Cancer.

[224]  Shusen Zheng,et al.  Increased circulating Lin−/lowCD33+HLA‐DR− myeloid‐derived suppressor cells in hepatocellular carcinoma patients , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[225]  C. Franceschi,et al.  Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[226]  Gerald C. Chu,et al.  Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. , 2014, Cancer discovery.

[227]  A. Troxel,et al.  A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme , 2014, Autophagy.

[228]  M. Sayegh,et al.  Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes , 2014, PloS one.

[229]  A. Reiner,et al.  Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[230]  L. Tong,et al.  Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. , 2013, Lung cancer.

[231]  M. Taura,et al.  HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway. , 2014, Cancer letters.

[232]  Guobin Liu,et al.  Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro , 2014, Cancer Cell International.

[233]  Emad Y Moawad.  Identifying the optimal dose of ritonavir in the treatment of malignancies , 2014, Metabolic Brain Disease.

[234]  E. Calabrese,et al.  How Radiotherapy Was Historically Used To Treat Pneumonia: Could It Be Useful Today? , 2013, The Yale journal of biology and medicine.

[235]  K. Schäkel,et al.  Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.

[236]  T. Misawa,et al.  Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice. , 2013, Surgery.

[237]  T. Misawa,et al.  Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation. , 2013, The Journal of surgical research.

[238]  S. Gambhir,et al.  A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide , 2013, Molecular Cancer Therapeutics.

[239]  H. Arnesen,et al.  Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. , 2013, Metabolism: clinical and experimental.

[240]  T. Misawa,et al.  Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. , 2013, Cancer letters.

[241]  J. Blay,et al.  Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. , 2013, European journal of cancer.

[242]  A. Gotoh,et al.  Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells , 2013, International journal of oncology.

[243]  Yingbin Ge,et al.  Endoplasmic Reticulum Stress Signaling Is Involved in Mitomycin C(MMC)-Induced Apoptosis in Human Fibroblasts via PERK Pathway , 2013, PloS one.

[244]  P. O'dwyer,et al.  Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy , 2013, Clinical Cancer Research.

[245]  J. Blay,et al.  CD4 lymphopenia to identify end-of-life metastatic cancer patients. , 2013, European journal of cancer.

[246]  M. Roberti,et al.  Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients , 2013, Innate immunity.

[247]  E. Androphy,et al.  Chloroquine Promotes Apoptosis in Melanoma Cells by Inhibiting BH3 domain Mediated PUMA Degradation , 2013, The Journal of investigative dermatology.

[248]  F. Ghiringhelli,et al.  Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity? , 2012, Trends in molecular medicine.

[249]  E. White,et al.  Effect of dual inhibition of apoptosis and autophagy in prostate cancer , 2012, The Prostate.

[250]  Jincun Zhao,et al.  Intranasal Treatment with Poly(I·C) Protects Aged Mice from Lethal Respiratory Virus Infections , 2012, Journal of Virology.

[251]  J. Dancey,et al.  Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[252]  Jincun Zhao,et al.  Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. , 2011, The Journal of clinical investigation.

[253]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[254]  A. Brenner,et al.  Common toxicities of mammalian target of rapamycin inhibitors , 2011, Targeted Oncology.

[255]  A. Hauschild,et al.  Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[256]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[257]  H. Ueno,et al.  Dendritic cells and immunity against cancer , 2011, Journal of internal medicine.

[258]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[259]  R. Mesquita,et al.  A new topical treatment protocol for oral hairy leukoplakia. , 2010, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[260]  C. Bergeron,et al.  Hemophagocytic syndrome revealing primary HHV-6 infection. , 2010, The Journal of pediatrics.

[261]  O. Jänne,et al.  Androgen receptor and androgen-dependent gene expression in lung , 2010, Molecular and Cellular Endocrinology.

[262]  V. Rohde,et al.  Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells , 2010, Neuro-oncology.

[263]  A. Justice,et al.  Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression , 2009, Journal of acquired immune deficiency syndromes.

[264]  Young Woo Park,et al.  Type II transmembrane serine proteases in cancer and viral infections. , 2009, Trends in molecular medicine.

[265]  J. Blay,et al.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. , 2009, Cancer research.

[266]  K. Sepkowitz,et al.  Nosocomial infections in patients with cancer. , 2009, The Lancet. Oncology.

[267]  N. Mori,et al.  An HIV protease inhibitor, ritonavir targets the nuclear factor‐kappaB and inhibits the tumor growth and infiltration of EBV‐positive lymphoblastoid B cells , 2009, International journal of cancer.

[268]  Yuquan Wei,et al.  Cell Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis Induced by Chloroquine in Human Breast Cancer Cell Line Bcap-37 , 2008, Cellular Physiology and Biochemistry.

[269]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[270]  J. Wastling,et al.  Thiazolides inhibit growth and induce glutathione‐S‐transferase Pi (GSTP1)‐dependent cell death in human colon cancer cells , 2008, International journal of cancer.

[271]  Yuquan Wei,et al.  [Effects of chloroquine diphosphate on proliferation and apoptosis of human leukemic K562 cells]. , 2008, Zhongguo shi yan xue ye xue za zhi.

[272]  C. Ryan,et al.  Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. , 2008, The Journal of urology.

[273]  P. Vestergaard,et al.  Adverse bone effects during pharmacological breast cancer therapy , 2008, Acta oncologica.

[274]  M. Ewer,et al.  Cardiotoxicity Profile of Trastuzumab , 2008, Drug safety.

[275]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[276]  J. Goodwin,et al.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[277]  S. Inoue,et al.  Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail Deleted , 2007, Journal of Virology.

[278]  Ralph Baric,et al.  A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice , 2007, PLoS pathogens.

[279]  T. Guise,et al.  Bone loss and fracture risk associated with cancer therapy. , 2006, The oncologist.

[280]  S. Madronich,et al.  Epidemic influenza and vitamin D , 2006, Epidemiology and Infection.

[281]  I. Shiojima,et al.  Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload , 2006, Hypertension.

[282]  Christie M. Orschell,et al.  Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer , 2006, Clinical Cancer Research.

[283]  P. Opolon,et al.  Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. , 2005, Anticancer research.

[284]  D. Murasko,et al.  Response of aged mice to primary virus infections , 2005, Immunological reviews.

[285]  G. Krejs,et al.  Diarrhea caused by primarily non-gastrointestinal infections , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[286]  A. Kentsis,et al.  Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[287]  Y. Ohtsuki,et al.  HIV-1 Protease Inhibitor, Ritonavir , 2004, Cancer Research.

[288]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[289]  Matthew R. Smith.  Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. , 2004, Urology.

[290]  P. André,et al.  Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. , 2004, Molecular cancer therapeutics.

[291]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[292]  C. Fraser,et al.  Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong , 2003, The Lancet.

[293]  C. Galanos,et al.  Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. , 2002, Cancer research.

[294]  M. Reitz,et al.  Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. , 2002, Blood.

[295]  D. Sawyer,et al.  Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity , 2002, Circulation.

[296]  S. Joel,et al.  DNA damage is able to induce senescence in tumor cells in vitro and in vivo. , 2002, Cancer research.

[297]  J. Correas,et al.  CHARACTERISTICS OF SIROLIMUS-ASSOCIATED INTERSTITIAL PNEUMONITIS IN RENAL TRANSPLANT PATIENTS , 2001, Transplantation.

[298]  P. Watts,et al.  Ganciclovir and Penciclovir, but Not Acyclovir, Induce Apoptosis in Herpes Simplex Virus Thymidine Kinasetransformed Baby Hamster Kidney Cells , 2001, Antiviral chemistry & chemotherapy.

[299]  E. Keller,et al.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. , 2000, Annual review of medicine.

[300]  P. Schultheiss,et al.  Clinical and laboratory findings associated with actual or suspected azoospermia in dogs: 18 cases (1979-1990). , 1992, Journal of the American Veterinary Medical Association.

[301]  A. Mantovani,et al.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock , 1991, Journal of Experimental Medicine.

[302]  R. K. Robins,et al.  Synthesis and Antitumor Activity of Ribavirin Imidates. A New Facile Synthesis of Ribavirin Amidine (1‐β‐D‐Ribofuranosyl‐1,2,4‐triazole‐3‐carboxamidine Hydrochloride). , 1989 .

[303]  R. K. Robins,et al.  Synthesis and antitumor activity of ribavirin imidates. A new facile synthesis of ribavirin amidine (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride). , 1989, Journal of medicinal chemistry.

[304]  R. Stuart-Harris,et al.  Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy. , 1983, Postgraduate medical journal.

[305]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[306]  K. Meyer.  Radiation-induced lymphocyte-immune deficiency. A factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. , 1970, Archives of surgery.

[307]  E. V. Powell.  ROENTGEN THERAPY OF LOBAR PNEUMONIA , 1938 .